Sandia National Laboratories has published an article on the longstanding and productive collaboration between Sandia’s Center for Integrated Nanotechnologies (CINT) and Imagion Biosystems’ R&D scientists.
Highlights of the collaboration cited in the article include Sandia scientists’ contributions to nanoparticle size and shape analysis, the co-development of a new process for high-yield, precise-size nanoparticle production, and the successful transfer of the process to Imagion Biosystems’ clinical-trials nanoparticles manufacturing partner, ChemConnection.
Read Magnetic nanoparticles leap from lab bench to breast cancer clinical trials at Sandia National Laboratories.
Dr. Nina Webster Joins IBX Board of Directors
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging